State of the art R&D centres for pharmaceutical dosage development, Active Pharmaceutical Ingredients and BA/BE centre located in NOIDA (India) with 400+ scientists.

R&D Dosages focuses on development of immediate release (IR) products (coated/ uncoated tablets, bi-layered tablets, hard gelatine capsules, powder for oral suspensions) and novel drug delivery system (NDDS)-based products (extended/delayed/sustained release, orally disintegrating and chewable/dispersible tablets), ophthalmic, injectable products and formulations for veterinary business. Capable of developing multiple products per annum to support registration in the US (United States), Europe (EU), Canada (CA), Japan (JP), China, Australia (AUS), South Africa (SA), Brazil & Rest of the World (ROW) markets. Our developed technologies and products are IP, Regulatory and Quality compliant.

The BA/BE centre has approval from CDSCO (DCGI), certifications from NABL (India), CAP (U.S) and is being inspected by US-FDA (9 times), INFARMED (Portugal, once), NPRA (Malaysia, twice), EMA (Europe, once) BAGES/AGES (Austria, once), ANVISA (Brazil, once) and Kazakhstan for study specific approvals/ marketing authorizations. Has experience in conducting more than 600 studies.

Our R&D continues to lead to new, innovative processes and new knowledge-driven products that increase the efficiencies of our production and allow us to capitalise on opportunities for growth in competitive markets. As on September 30, 2019, we have filed 546 patent applications on various API, dosage form products and technologies in various jurisdictions.